Chimeric Antigen Receptor T Cells Targeting Glypican-3

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 15, 2019

Primary Completion Date

May 28, 2021

Study Completion Date

December 3, 2021

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

CAR-GPC3 T Cells

CAR-GPC3 T Cells injection

Trial Locations (6)

200001

Renji Hospital Shang Hai Jiaotong Unversity of Medicine, Shanghai

Zhongshan Hospital of Fudan University, Shanghai

210002

The 81st Hospital of Chinese PLA, Nanjing

310006

The First Affiliated Hospital Zhejiang University, Hangzhou

450000

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510000

Nanfang Hospital of Southern Medical University, Guangzhou

Sponsors
All Listed Sponsors
collaborator

NanJing PLA 81 Hospital

OTHER

collaborator

First Affiliated Hospital of Zhejiang University

OTHER

collaborator

RenJi Hospital

OTHER

lead

CARsgen Therapeutics Co., Ltd.

INDUSTRY

NCT03884751 - Chimeric Antigen Receptor T Cells Targeting Glypican-3 | Biotech Hunter | Biotech Hunter